These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30865317)

  • 1. Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration.
    Liu XI; Dallmann A; Wang YM; Green DJ; Burnham JM; Chiang B; Wu P; Sheng M; Lu K; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2019 Aug; 59(8):1130-1143. PubMed ID: 30865317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
    Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
    JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients.
    Temrikar ZH; Suryawanshi S; Meibohm B
    Paediatr Drugs; 2020 Apr; 22(2):199-216. PubMed ID: 32052309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric Dose Selection for Therapeutic Proteins.
    Malik PRV; Temrikar ZH; Chelle P; Edginton AN; Meibohm B
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S193-S206. PubMed ID: 34185910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
    Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
    Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Weight Thresholds for Pediatric Patients to Use Adult Dosage of Therapeutic Monoclonal Antibodies.
    Yang N; Xu MC; Yao Z
    J Clin Pharmacol; 2019 Oct; 59(10):1309-1318. PubMed ID: 31050000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food-Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012-2022.
    Tunehag KR; George B; Samuels S; Vo K; Arya V; Abulwerdi G; Burckart GJ
    J Clin Pharmacol; 2024 Jun; 64(6):697-703. PubMed ID: 38294346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and considerations for development of therapeutic proteins in pediatric patients.
    Zhang Y; Wei X; Bajaj G; Barrett JS; Meibohm B; Joshi A; Gupta M
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S103-15. PubMed ID: 25707958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products.
    Eales B; Helal NA; Vattelana O; Kronfol MM; Fletcher EP; Wang YM; Burckart GJ; Vaidyanathan J; Seo SK; Nounou MI
    J Clin Pharmacol; 2024 Dec; 64(12):1594-1605. PubMed ID: 39149895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics.
    Ogasawara K; Alexander GC
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):914-921. PubMed ID: 30707505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory Perspective.
    Li RJ; Ma L; Kim H; Kim I; Hanes L; Altepeter T; Lee J; Liu J; Zhu H; Wang Y
    AAPS J; 2022 Jul; 24(4):79. PubMed ID: 35790574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020.
    Green FG; Park K; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S28-S35. PubMed ID: 34185898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
    Rioux N; Waters NJ
    Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
    Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
    Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants.
    Malik PRV; Edginton AN
    J Clin Pharmacol; 2020 Apr; 60(4):466-476. PubMed ID: 31729044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric and Adult Placebo Response Rates in Placebo-Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012-2020.
    Park K; Tran NK; Momper JD; Green DJ; Burckart GJ
    J Clin Pharmacol; 2022 Aug; 62(8):970-982. PubMed ID: 35118684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacometric Bridging Approach for U.S. Food and Drug Administration Approval and Identification of Topiramate Dosing Regimen for Pediatric Patients 2-9 Years of Age With Epilepsy.
    Marathe A; Liu C; Kapcala LP; Hershkowitz N; Men A; Uppoor R; Mehta M; Wang Y
    J Pharm Sci; 2019 Apr; 108(4):1598-1603. PubMed ID: 30468826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.